Argenx and Zai Lab's efgartigimod alfa injection receives NMPA approval for generalized myasthenia gravis in China.
Argenx and Zai Lab announced the approval of efgartigimod alfa injection (subcutaneous injection) for generalized myasthenia gravis in China. This marks the first and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China. The approval is based on consistent clinical benefit and safety profile of efgartigimod SC compared to IV, demonstrated in the Phase 3 ADAPT-SC study.
July 16, 2024
4 Articles